The approval of TEPOXX in Japan marks another significant milestone in our mission to expand access to this critical ...

SIGA Technologies (NASDAQ:SIGA) announced Thursday that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved ...

It’s déjà vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug again missed the mark on a key measure of disease resolution.

On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment ...

Siga Technologies Inc. (SIGA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...

(RTTNews) - SIGA Technologies, Inc. (SIGA), Thursday announced that its tecovirimat 200 mg capsules, traded as TEPOXX, has secured regulatory approval in Japan for the treatment of smallpox, mpox, ...

Dec 10 (Reuters) - Siga Technologies' (SIGA.O), opens new tab antiviral drug did not reduce the time to lesion resolution or have an effect on pain among adults affected by the clade II strain of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Japan approves SIGA's TEPOXX, the first antiviral for orthopoxviruses, for smallpox, mpox, cowpox, and vaccine-related complications. Approval is based on 15 clinical trials and pivotal animal ...

The antiviral drug tecovirimat, from Siga Technologies (SIGA), did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low ...